Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting

International Journal of Infectious Diseases

Volumn 12, Issue 6, 2008, Pages 582-586

  Manosuthi, Weerawat ^a,b   Prasithsirikul, Wisit ^a   Chumpathat, Noppanath ^a   Suntisuklappon, Bussakorn ^a   Athichathanabadi, Chatiya ^a   Chimsuntorn, Sukanya ^a   Sungkanuparph, Somnuek ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; HIV; Hyperlactatemia; Mortality; Risk factor

Indexed keywords

ALANINE AMINOTRANSFERASE; DIDANOSINE; LACTIC ACID; STAVUDINE; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK FACTOR; TREATMENT DURATION;

ACIDOSIS, LACTIC; ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LACTIC ACID; MALE; POVERTY; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 54349115711     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2007.12.005     Document Type: Article

References (23)

1. Brinkman K., Smeitink J.A., Romijn J.A., and Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354 (1999) 1112-1115
2. Côté H.C., Brumme Z.L., Craib K.J., Alexander C.S., Wynhoven B., Ting L., et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346 (2002) 811-820
3. Lewis W., and Dalakas M.C. Mitochondrial toxicity of antiviral drugs. Nat Med 1 (1995) 417-422
4. Falcó V., Rodríguez D., Ribera E., Martínez E., Miró J.M., Domingo P., et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 34 (2002) 838-846
5. Miller K.D., Cameron M., Wood L.V., Dalakas M.C., and Kovacs J.A. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 133 (2000) 192-196
6. Carr A. Lactic acidemia in infection with human immunodeficiency virus. Clin Infect Dis 36 Suppl 2 (2003) S96-S100
7. Tsiodras S., Mantzoros C., Hammer S., and Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 160 (2000) 2050-2056
8. John M., Moore C.B., James I.R., Nolan D., Upton R.P., McKinnon E.J., et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 15 (2001) 717-723
9. Boubaker K., Flepp M., Sudre P., Furrer H., Haensel A., Hirschel B., et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 33 (2001) 1931-1937
10. Gerard Y., Maulin L., Yazdanpanah Y., De La Tribonnière X., Amiel C., Maurage C.A., et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 14 (2000) 2723-2730
11. Bonnet F., Bonarek M., Morlat P., Mercié P., Dupon M., Gemain M.C., et al. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis 36 (2003) 1324-1328
12. Butt A.A. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read 13 (2003) 344-348
13. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17 Suppl 1 (2003) S141-S148
14. Fleischer R., Boxwell D., and Sherman K.E. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 38 (2004) e79-e80
15. Boffito M., Marietti G., Audagnotto S., Raiter R., and Di Perri G. Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors. Clin Infect Dis 34 (2002) 558-559
16. Schambelan M., Benson C.A., Carr A., Currier J.S., Dubé M.P., Gerber J.G., et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 31 (2002) 257-275
17. Lonergan J.T., Behling C., Pfander H., Hassanein T.I., and Mathews W.C. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 31 (2000) 162-166
18. Hocqueloux L., Alberti C., Feugeas J.P., Lafaurie M., Lukasiewicz E., Bagnard G., et al. Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients. HIV Med 4 (2003) 18-23
19. John M., and Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 15 (2002) 23-29
20. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2006 revision. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO); 2006.
21. Carr A., Morey A., Mallon P., Williams D., and Thorburn D.R. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 357 (2001) 1412-1414
22. Arenas-Pinto A., Grant A.D., Edwards S., and Weller I.V. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect 79 (2003) 340-343
23. Bolhaar M.G., and Karstaedt A.S. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 45 (2007) 254-260